Cancer drug developer Calithera Biosciences Inc. is seeking $80 million through an initial public offering, the company said in a Securities and Exchange Commission filing Monday.
The South San Francisco company, which would trade on the NASDAQ exchange as “CALA,” has long been rumored as an IPO candidate, especially since so-called crossover funds backed Calithera’s $35 million Series D round last fall.
What’s more, Calithera CEO Susan Molineaux, who led Proteolix Inc. into a 2009 deal that delivered the multiple myeloma drug Kyprolis to Onyx Pharmaceuticals Inc., earlier this year hired William Waddill as Calithera’s chief financial officer.
Help employers find you! Check out all the jobs and post your resume.
